309
Views
12
CrossRef citations to date
0
Altmetric
BRIEF REPORT

Gene expression analysis in blood of ultra-high risk subjects compared to first-episode of psychosis patients and controls

, , , , , , , , , , , , , & show all
Pages 441-446 | Received 22 Jan 2015, Accepted 30 Apr 2015, Published online: 18 Jun 2015

References

  • Bassett AS, Chow EW, Husted J, Weksberg R, Caluseriu O, Webb GD, et al. 2005. Clinical features of 78 adults with 22q11 Deletion Syndrome. Am J Med Genet A 138:307–313.
  • Boggs JM. 2006. Myelin basic protein: a multifunctional protein. Cell Mol Life Sci 63:1945–1961.
  • Chen M, Gutierrez GJ, Ronai ZA. 2011. Ubiquitin-recognition protein Ufd1 couples the endoplasmic reticulum (ER) stress response to cell cycle control. Proc Natl Acad Sci USA 108: 9119–9124.
  • Christofolini DM, Bellucco FT, Ota VK, Belangero SI, Cernach MC, Gadelha, A, et al. 2011. Assessment of 22q11.2 copy number variations in a sample of Brazilian schizophrenia patients. Schizophr Res 132:99–100.
  • Ciechanover A. 1994. The ubiquitin-proteasome proteolytic pathway. Cell 79:13–21.
  • Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, et al. 2003. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 60:443–456.
  • De Luca A, Pasini A, Amati F, Botta A, Spalletta G, Alimenti S, et al. 2001. Association study of a promoter polymorphism of UFD1L gene with schizophrenia. Am J Med Genet 105: 529–533.
  • Demjaha A, Valmaggia L, Stahl D, Byrne M, McGuire P. 2012. Disorganization/cognitive and negative symptom dimensions in the at-risk mental state predict subsequent transition to psychosis. Schizophr Bull 38:351–359.
  • Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, et al. 2012. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69:220–229.
  • Hattori T, Shimizu S, Koyama Y, Emoto H, Matsumoto Y, Kumamoto N, et al. 2014. DISC1 (disrupted-in-schizophrenia-1) regulates differentiation of oligodendrocytes. PLoS One 9:e88506.
  • Kubicki M, Park H, Westin CF, Nestor PG, Mulkern RV, Maier SE, et al. 2005. DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. Neuroimage 26: 1109–1118.
  • Kumarasinghe N, Beveridge NJ, Gardiner E, Scott RJ, Yasawardene S, Perera A, et al. 2013. Gene expression profiling in treatment-naive schizophrenia patients identifies abnormalities in biological pathways involving AKT1 that are corrected by antipsychotic medication. Int J Neuropsychopharmacol 16: 1483–1503.
  • Leal MF, Belangero PS, Figueiredo EA, Cohen C, Loyola LC, Andreoli CV, et al. 2015. Identification of suitable reference genes for gene expression studies in tendons from patients with rotator cuff tear. PLoS One 10:e0118821.
  • Lieberman JA. 1999. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 46:729–739.
  • Martins-de-Souza D. 2010. Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia. J Psychiatr Res 44:149–156.
  • Martins-de-Souza D. 2011. Proteomics as a tool for understanding schizophrenia. Clin Psychopharmacol Neurosci 9:95–101.
  • Martins-de-Souza D, Maccarrone G, Wobrock T, Zerr I, Gormanns P, Reckow S. et al. 2010. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res 44:1176–1189.
  • Matthews PR, Eastwood SL, Harrison PJ. 2012. Reduced myelin basic protein and actin-related gene expression in visual cortex in schizophrenia. PLoS One 7:e38211.
  • McGlashan TH, Johannessen JO. 1996. Early detection and intervention with schizophrenia: rationale. Schizophr Bull 22:201–222.
  • Myung J, Kim KB, Crews CM. 2001. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 21: 245–273.
  • Narayan S, Kass KE, Thomas EA. 2007. Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte-related genes in the mouse brain. J Neurosci Res 85:757–765.
  • Novelli G, Mari A, Amati F, Colosimo A, Sangiuolo F, Bengala M, et al. 1998. Structure and expression of the human ubiquitin fusion-degradation gene (UFD1L). Biochim Biophys Acta 1396:158–162.
  • Ota VK, Belangero SI, Gadelha A, Bellucco FT, Christofolini DM, Mancini TI, et al. 2010. The UFD1L rs5992403 polymorphism is associated with age at onset of schizophrenia. J Psychiatr Res 44:1113–1115.
  • Ota VK, Berberian AA, Gadelha A, Santoro ML, Ottoni GL, Matsuzaka CT, et al. 2013. Polymorphisms in schizophrenia candidate gene UFD1L may contribute to cognitive deficits. Psychiatry Res 209:110–113.
  • Park S, Isaacson R, Kim HT, Silver PA, Wagner G. 2005. Ufd1 exhibits the AAA–ATPase fold with two distinct ubiquitin interaction sites. Structure 13:995–1005.
  • Parlapani E, Schmitt A, Erdmann A, Bernstein HG, Breunig B, Gruber O, et al. 2009. Association between myelin basic protein expression and left entorhinal cortex pre-alpha cell layer disorganization in schizophrenia. Brain Res 1301:126–134.
  • Sullivan PF, Kendler KS, Neale MC. 2003. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 60:1187–1192.
  • Ye Y, Meyer HH, Rapoport TA. 2001. The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature 414:652–656.
  • Yung AR, McGorry PD. 1996. The prodromal phase of first- episode psychosis: past and current conceptualizations. Schizophr Bull 22:353–370.
  • Ziermans TB, Schothorst PF, Sprong M, van Engeland H. 2011. Transition and remission in adolescents at ultra-high risk for psychosis. Schizophr Res 126:58–64.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.